CVS Health is broadening access to Novo Nordisk’s popular weight loss drug, Wegovy, for patients covered by its pharmacy benefit manager, Caremark. Starting July 1, Caremark will prioritize Wegovy on its formularies, making it the preferred GLP-1 drug for obesity treatment. This partnership aims to provide the drug at a more affordable price through negotiated discounts. While insured patients may benefit from lower premiums or copays, uninsured individuals can purchase Wegovy for $499 at CVS pharmacies nationwide. The move aligns with efforts to increase accessibility and affordability of FDA-approved medications.
— new from CNBC
